Placeholder Banner

BIO Submits Comments on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule

March 20, 2019

BIO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule.

BIO is extremely concerned the Agency continues to erode the value of the Medicare benefit for seniors, placing patient access at risk. This proposed rule prioritizes cost containment policies over patient healthcare needs. BIO respectfully requests the Agency and Administration instead focus on holistic solutions to balance the financial sustainability of the Medicare program, while addressing patient out-of-pocket cost and access to appropriate treatment. In the comments, BIO provides specific recommendations for how CMS can improve the proposed rule and ensure greater access for patients while directly reducing OOP costs.

Download Full Comments Below
FINAL BIO Comment Letter MA And Part D Proposed Rule 1 25 19
See the full comment letter here:
Discover More
In a recent letter, BIO’s Jim Greenwood commended Representative Steil (R-WI) for introducing the “Helping Startups Continue to Grow Act,” which extends the exemption afforded to Emerging Growth Companies under the JOBS Act from certain executive…
In a letter to Chairman Grassley (R-IA) and Ranking Member Wyden (D-OR), the leaders of the Senate Finance Committee, state biotech associations warn that the Committee’s proposed redesign of Medicare Part D puts new, innovative treatments for…
The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance titled Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and…